Published in Cancer Treat Res on January 01, 2005
Evaluation of myeloid cells (tumor-associated tissue eosinophils and mast cells) infiltration in different grades of oral squamous cell carcinoma. Indian J Med Paediatr Oncol (2016) 1.39
Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano (2011) 1.04
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res (2014) 0.86
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program (2009) 0.79
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.43
MUC1 immunobiology: from discovery to clinical applications. Adv Immunol (2004) 1.79
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res (2008) 1.66
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) (2012) 1.39
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (2004) 1.36
Immune response as a biomarker for cancer detection and a lot more. N Engl J Med (2005) 1.35
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res (2005) 1.24
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22
Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol (2007) 1.21
Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol (2011) 1.16
Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.11
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol (2005) 1.09
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol (2002) 1.07
MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain. J Biol Chem (2011) 1.06
Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis. Pancreas (2010) 1.05
Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis (2002) 1.03
Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control (2010) 1.03
Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res (2006) 1.03
Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem (2009) 1.00
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res (2010) 0.99
MUC1 immunotherapy is here to stay. Expert Opin Biol Ther (2012) 0.98
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol (2007) 0.98
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A (2009) 0.97
Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol (2008) 0.94
Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis (2004) 0.94
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget (2013) 0.92
Incidence rate of breast cancer in young women. JAMA (2013) 0.91
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol (2008) 0.91
Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol (2010) 0.91
Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology (2003) 0.90
Cancer immunology. Curr Opin Immunol (2011) 0.87
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol (2009) 0.86
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother (2010) 0.86
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol (2010) 0.86
DNA vaccines for cancer too. Cancer Immunol Immunother (2005) 0.85
Cancer vaccines: a promising cancer therapy against all odds. Future Oncol (2007) 0.84
Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen. Oncoimmunology (2012) 0.84
Human papillomavirus vaccine for cancer prevention. N Engl J Med (2009) 0.84
Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother (2012) 0.83
Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci (2005) 0.83
Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice. Ann N Y Acad Sci (2009) 0.82
AACR Cancer Progress Report 2012. Clin Cancer Res (2012) 0.82
Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol (2006) 0.82
Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells. Breast Cancer Res (2006) 0.80
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy. Cancer Immunol Immunother (2008) 0.79
Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol (2004) 0.78
Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells. Oncoimmunology (2013) 0.78
Mucins in gastrointestinal cancers. Cancer Chemother Biol Response Modif (2003) 0.78
Early in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology (2013) 0.77
Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunol Res (2013) 0.77
Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas. Ann N Y Acad Sci (2013) 0.77
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes. J Immunol (2013) 0.77
Preventive immunization of aged and juvenile non-human primates to β-amyloid. J Neuroinflammation (2012) 0.77
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen. J Immunol (2013) 0.76
Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy. J Biomed Biotechnol (2006) 0.75
Cancer vaccines: emphasis on pediatric cancers. Curr Pharm Des (2010) 0.75